Alford Brady, MD
Internal Medicine · Valdosta, GANPI 1467449272
Payments from drug & device makers
Across 197 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$723
- Novo Nordisk$344
- Pfizer$341
- Johnson & Johnson$193
- Lilly USA, LLC$166
- Dexcom, Inc.$121
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,12497%
- Education$903%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 37 | $723 |
| Novo Nordisk | 25 | $344 |
| Pfizer | 23 | $341 |
| Johnson & Johnson | 22 | $193 |
| Lilly USA, LLC | 10 | $166 |
| Dexcom, Inc. | 6 | $121 |
| Sanofi-aventis U.S. LLC | 8 | $113 |
| Abbott | 6 | $113 |
| Novartis | 5 | $109 |
| Otsuka America Pharmaceutical, Inc. | 5 | $103 |
| Merck | 7 | $101 |
| GSK | 6 | $80 |
| Axsome Therapeutics, Inc. | 4 | $74 |
| Shield Therapeutics Inc | 2 | $63 |
| AstraZeneca | 4 | $58 |
| AbbVie | 3 | $47 |
| Nestle Healthcare Nutrition Inc. | 2 | $46 |
| Lundbeck LLC | 3 | $45 |
| Paratek Pharmaceuticals, Inc. | 2 | $42 |
| Eisai Inc. | 2 | $42 |
| Dynavax Technologies Corporation | 2 | $41 |
| Amgen | 2 | $29 |
| Boston Scientific | 1 | $28 |
| Exact Sciences | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Circassia Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Almatica Pharma LLC | 1 | $13 |
How this compares
$3,214 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 193 | $178,523 |
| EliquisApixaban | 146 | $139,636 |
| JardianceEmpagliflozin | 132 | $116,668 |
| OzempicSemaglutide | 40 | $64,286 |
| XareltoRivaroxaban | 43 | $52,377 |
| MounjaroTirzepatide | 49 | $52,313 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 58 | $44,319 |
| TradjentaLinagliptin | 33 | $28,935 |
| JanumetSitagliptin Phos/Metformin Hcl | 35 | $28,258 |
| FarxigaDapagliflozin Propanediol | 35 | $27,080 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $27,015 |
| MyrbetriqMirabegron | 46 | $26,730 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 164 | $26,280 |
| TrulicityDulaglutide | 26 | $25,435 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $14,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $101 | $206,781228 claims |
| Boehringer IngelheimJardiance, Tradjenta | $15 | $145,603165 claims |
| PfizerEliquis | $341 | $139,636146 claims |
| Lilly USA, LLCMounjaro, Trulicity | $166 | $77,74875 claims |
| Novo NordiskOzempic | $344 | $64,28640 claims |
| Johnson & JohnsonXarelto | $193 | $52,37743 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $58 | $42,25566 claims |
| Astellas Pharma US IncMyrbetriq | $723 | $26,73046 claims |
| GSKBreo Ellipta | $80 | $14,07114 claims |
| AbbVieSynthroid | $47 | $4,43054 claims |
| Almatica Pharma LLCSertraline Hcl | $13 | $2,988415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Valdosta
- Anna LedfordValdosta$108K
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.